By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Allergan Inc. v. Apotex Inc. et. al.
1:07-cv-00278; filed May 21, 2007 in the District Court of Delaware
Infringement of U.S. Patent Nos. 5,424,078 ("Aqueous Ophthalmic Formulations and Methods for Preserving Same," issued June 13, 1995), 6,562,873 ("Compositions Containing Therapeutically Active Components Having Enhanced Solubility," issued May 13, 2003), 6,627,210 ("Compositions Containing alpha-2-Adrenergic Agonist Components," issued September 30, 2003), 6,641,834 (same title, issued November 4, 2003), and 6,673,337 (same title, issued January 6, 2004) following a paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Allergan's Alphagan® P (brimonidine tartrate ophthalmic solution, used to treat glaucoma). View the complaint here.
Iowa State University Research Foundation, Inc. v. Monsanto Company et. al.
4:07-cv-00221; filed May 21, 2007 in the Southern District of Iowa
Infringement of U.S. Patent Nos. 5,534,425 ("Soybeans Having Low Linolenic Acid Content and Method of Production," issued July 9, 1996) and 5,710,369 ("A16 soybeans having low linolenic acid content and descendents," issued January 20, 1998) based on Monsanto's Vistive® soybean program. View the complaint here.
Takeda Pharmaceuticals North America, Inc. et. al. v. Sandoz, Inc.
3:07-cv-02341; filed May 18, 2007 in the District Court of Delaware
Infringement of U.S. Patent Nos. 5,965,584 ("Pharmaceutical Composition," issued October 12, 1999), 6,329,404 (same title, issued December 11, 2001), 6,166,043 (same title, issued December 26, 2000), 6,172,090 (same title, issued January 9, 2001), 6,211,205 (same title, issued April 3, 2001), 6,271,243 (same title, issued August 7, 2001), and 6,303,640 (same title, issued October 16, 2001) following a paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Takeda's Actos® (pioglitazone hydrochloride, used to treat type II diabetes). View the complaint here.
Comments